Plus Deferred Long Term Liab from 2010 to 2025
| PSTV Stock | USD 1.26 0.03 2.44% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 142.6 K | Current Value 149.7 K | Quarterly Volatility 67.3 K |
Check Plus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Plus Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 337.7 K, Selling General Administrative of 10.2 M or Selling And Marketing Expenses of 637 K, as well as many indicators such as Price To Sales Ratio of 1.22, Dividend Yield of 0.0022 or Days Sales Outstanding of 46.47. Plus financial statements analysis is a perfect complement when working with Plus Therapeutics Valuation or Volatility modules.
Plus | Deferred Long Term Liab |
Latest Plus Therapeutics' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Plus Therapeutics over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Plus Therapeutics' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Plus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Plus Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 64,771 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 103.86 | |
| Mean Deviation | 64,771 | |
| Median | 124,000 | |
| Standard Deviation | 67,274 | |
| Sample Variance | 4.5B | |
| Range | 149.7K | |
| R-Value | 0.89 | |
| Mean Square Error | 997.2M | |
| R-Squared | 0.79 | |
| Slope | 12,594 | |
| Total Sum of Squares | 67.9B |
Plus Deferred Long Term Liab History
About Plus Therapeutics Financial Statements
Plus Therapeutics investors use historical fundamental indicators, such as Plus Therapeutics' Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Plus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 142.6 K | 149.7 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.